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Abstract: The aim of this study was to identify an anti-obesity peptide from Allomyrina dichotoma
and investigate the lipid metabolic mechanism. Enzymatically hydrolyzed A. dichotoma larvae were
further separated using tangential flow filtration and consecutive chromatographic processes. Finally,
an anti-obesity peptide that showed the highest inhibitory effect on lipid accumulation was obtained,
and the sequence was Glu-Ile-Ala-Gln-Asp-Phe-Lys-Thr-Asp-Leu (EIA10). EIA10 decreased lipid
aggregation in vitro and significantly reduced the accumulation of body weight gain, liver weight,
and adipose tissue weight in high-fat-fed mice. Compared with the control group, the levels of
total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL), insulin, and
homeostasis model assessment of insulin resistance (HOMA-IR) in the high-fat diet (HFD) group
increased significantly, and the content of high-density lipoprotein cholesterol (HDL) in the serum
decreased significantly. On the contrary, the levels of TC, TG, and insulin in the EIA10 group
decreased significantly, and the HDL content increased significantly compared with the HFD group.
Additionally, EIA10 dramatically decreased mRNA and protein levels of transcription factors involved
in lipid adipogenesis. Taken together, our results suggest that EIA10 could be a promising agent for
the treatment and prevention of obesity.
Keywords: Allomyrina dichotoma larvae; peptide; lipid metabolism; anti-obesity
1. Introduction
The Food and Agricultural Organization of the United Nations (FAO) has recently proposed that
edible insects be used, such as the rhinoceros beetle (Alphitobius diaperinus), as potential food resources
due to their high-quality proteins and vitamins [1,2], which may alleviate food shortage and delay
global warming. The Japanese rhinoceros beetle, Allomyrina dichotoma, inhabits broad-leaved forests
in mountainous habitats and lives for approximately 12 months in the wild [3]. Hence, breeding
these beetles would save space, time, and human labor owing to their short generation times and
small body sizes [4]. A. dichotoma belongs to the family Scarabaeidae and the order Coleoptera. The
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larvae have been traditionally used to treat liver-related diseases and diabetes [5]. Several studies have
demonstrated that a boiled extract of A. dichotoma has anti-hepatofibrotic, anti-neoplastic, antibiotic,
anti-diabetic, and anti-obesity effects [6–8].
Abnormal lipid metabolism refers to the abnormal synthesis, degradation, digestion, and
absorption of lipid substances in the body, resulting in excessive lipid in various tissues, which affects
various body functions [9]. Abnormal lipid metabolism is mainly caused by excessive energy storage,
manifested as cholesterol, triglyceride (TG), and excessive free fatty acid (FFA) levels [10] and causes
fatty liver, obesity, diabetes, hyperlipidemia, hypertension, and coronary heart disease [11,12]. Obesity,
fat accumulation in abdominal or abdominal viscera, is characterized by the clinical manifestation
of abdominal enlargement as well as waist circumference and waist–hip ratio increase. This chronic
metabolic disorder is a major global health problem that has been rising rapidly in recent years [13].
Obesity is a major risk factor for systemic inflammation, hyperlipidemia, insulin resistance, and
cardiovascular disease [14]. Orlistat, an effective inhibitor of the pancreatic and gastric lipases in
the gastrointestinal tract, is now the drug the most widely employed as an anti-obesity medication.
However, its usage results in many undesirable intestinal reactions such as fatty feces, diarrhea, and
abdominal discomfort [15].
Despite the high prevalence of obesity worldwide, not many new treatments have been approved.
Therefore, there is an urgent need for new treatments for obesity. At present, anti-obesity peptide
research is a hotspot, with focus on the inhibition of pancreatic lipase activity and appetite suppression.
Egg white hydrolysates prepared by proteases and pepsin digestion reduced the lipid content of liver,
muscle, and body fat in rats [16,17]. The effects of egg hydrolysates and black soybean hydrolysates
on human markers of diabetes and obesity have drawn attention to their absorption and molecular
targets [18]. Camel milk peptides possess anti-diabetic and anti-obesity effects [19]. Similarly, fish
collagen peptides, derived from water-hydrolyzed components, reduced lipid accumulation and the
expression of CCAAT/enhancer-binding protein-α (C/EBP-α) and peroxisomal proliferator-activated
receptor γ (PPARγ) genes during the differentiation of 3T3-L1 cells [20]. Oral supplementation with
collagen fragments reduces body fat and body weight and improves cytokines [21].
However, to our knowledge, this is the first study investigating the effects of a peptide
from A. dichotoma larvae, EIAQDFKTDL (Glu-Ile-Ala-Gln-Asp-Phe-Lys-Thr-Asp-Leu, EIA10), on
an experimental animal model widely used by pharmaceutical companies to test anti-obesity agents
and insulin sensitizers. Our aim was to investigate the improvement in lipid metabolism induced by
EIA10 in high-fat diet (HFD)-fed mice characterized by early onset of obesity and several physiological
abnormalities of obesity. We hypothesized that ameliorative lipid metabolism due to EIA10 could help
to reduce obesity and ameliorate obesity-related metabolic disorders in obese subjects.
2. Results and Discussion
2.1. Isolation, Purification, and Identification of Novel Peptide, EIA10
Recent reports show that food proteins can be converted into biologically active peptides by
hydrolysis. In this study, we purified 11 (Figure 1A) enzymatic protein hydrolysates (EPHs) from
A. dichotoma larvae using ultrafiltration (UF) and ion-exchange chromatography (IEC) to identify
the fraction with anti-lipid accumulation activity. The activity was performed by measuring the
anti-adipogenic effects of EPHs in 3T3-L1 cells. The optimal concentration was selected by cell viability
test (data in Supplementary Materials file). Using UF, five fractions, U-1 (<1 kDa), U-2 (1-5 kDa),
U-3 (5-10 kDa), U-4 (10-100 kDa), and U-5 (>100 kDa), were obtained. Among them, U-4 showed
the highest anti-adipogenic effect (23.9%) at 62.5 µg/mL of sample concentration and was therefore
subjected to IEC (Figure 1B) by which it showed good separation into constituent peaks, i.e., A, B, C,
and D, at 215 nm (Figure 1C, upper panel), which were collected and freeze-dried. Peak C showed the
highest anti-adipogenic effect (26.9%) at 31.25 µg/mL of sample concentration (Figure 1C, lower panel)
and was subsequently separated into C1, C2, C3, and C4. Subsequent separation and identification of
Int. J. Mol. Sci. 2020, 21, 8537 3 of 18
anti-obesity peptides from the C-4 fraction were performed by reversed-phase-HPLC and nanoUPLC
Orbitrap Fusion Lumos MS (Figure 1D, Table 1). As Glu-Ile-Ala-Gln-Asp-Phe-Lys-Thr-Asp-Leu
(EIA10) had 30.22% of lipid accumulation in the 3T3-L1 cells (Table 1), we therefore selected EIA10 for
subsequent experiments.
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Figure 1. Inhibitory effect of Allomyrina dichotoma larvae enzyme hydrolysate on lipid accumulation. 
(A) Inhibition of adipocyte differentiation by enzymatic hydrolysates of A. dichotoma larvae. (B) Anti-
obesity activity of fractions of A. dichotoma enzymatic hydrolysate classified by molecular weight. (C) 
Anti-obesity activity (upper panel) and ion-exchange chromatography (lower panel) of 10‒100 kDa 
ultrafiltration fraction. (D) Anti-obesity activity (upper panel) and reversed-phase column fractional 
chromatogram (lower panel) for preparative ion-exchange chromatography of peak C from (C). Lipid 
accumulation was measured by Oil Red O staining; untreated 3T3-L1 cells were used as control. PM: 
Promod 278P; AP: Alphalase NP; AC: Vision Biochem, Alcalase; NT: Neutrase; PMX: PS Pepsin 
Protamex; P: Pancreatin; AK: Food Pro Alkaline protease; PNP: Protease NP; TS: Trypsin. Data are 
expressed as mean ± standard error of the mean. * p < 0.05 vs. control (CON) cells. (n = 3 per group). 
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1 KLPFQR(Lys-Leu-Pro-Phe-Gln-Arg) 6 C37 H61 N11 O8 787 57.85
2 STELLIR(Ser-Thr-Glu-Leu-Leu-Ile-Arg) 7 C36 H66 N10 O12 830 59.04
3 EIAQDFK(Glu-Ile-Ala-Gln-Asp-Phe-Lys) 7 C38 H59 N9 O13 849 52.20
4 HLQLAIR(His-Leu-Gln-Leu-Ala-Ile-Arg) 7 C38 H67 N13 O9 849 63.26
5 AVQGLLK(Ala-Val-Gln-Gly-Leu-Leu-Lys) 7 C33 H61 N9 O9 727 48.40
6 IAQGGVLP(Ile-Ala-Gln-Gly-Gly-Val-Leu-Pro) 8 C34 H59 N9 O10 753 38.01
7 NDEELNKLL(Asn-Asp-Glu-Glu-Leu-Asn-Lys-Leu-Leu) 9 C46 H78 N12 O18 1086 39.44
8 AGLQFPVGR(Ala-Gly-Leu-Gln-Phe-Pro-Val-Gly-Arg) 9 C43 H69 N13 O11 943 33.70
9 YRPGTVALR(Tyr-Arg-Pro-Gly-Thr-Val-Ala-Leu-Arg) 9 C46 H77 N15 O12 1031 40.63
10 KSTGGKAPR(Lys-Ser-Thr-Gly-Gly-Lys-Ala-Pro-Arg) 9 C37 H68 N14 O12 900 48.40
11 KQLATKAAR(Lys-Gln-Leu-Ala-Thr-Lys-Ala-Ala-Arg) 9 C42 H79 N15 O12 985 94.26
12 RFQSSAVMA(Arg-Phe-Gln-Ser-Ser-Ala-Val-Met-Ala) 9 C42 H69 N13 O13 S1 995 57.47
13 TLSDYNIQK(Thr-Leu-Ser-Asp-Tyr-Asn-Ile-Gln-Lys) 9 C47 H76 N12 O17 1080 68.00
14 NKLLSGVTIA(Asn-Lys-Leu-Leu-Ser-Gly-Val-Thr-Ile-Ala) 10 C45 H82 N12 O14 1014 77.76
* 15 EIAQDFKTDL(Glu-Ile-Ala-Gln-Asp-Phe-Lys-Thr-Asp-Leu) 10 C52 H82 N12 O19 1178 30.22
16 ALNQAWAFLK(Ala-Leu-Asn-Gln-Ala-Trp-Ala-Phe-Leu-Lys) 10 C56 H84 N14 O13 1160 57.47
17 AERVGAGAPVY(Ala-Glu-Arg-Val-Gly-Ala-Gly-Ala-Pro-Val-Try) 11 C48 H76 N14 O15 1088 35.06
18 RIVDFHMLESR(Arg-Ile-Val-Asp-Phe-His-Met-Leu-Glu-Ser-Arg) 11 C61 H99 N19 O17 S1 1401 41.94
19 SGVTIAQGGVLP(Ser-Gly-Val-Thr-Ile-Ala-Gln-Gly-Gly-Val-Leu-Pro) 12 C48 H83 N13 O16 1097 68.00
20 APRKQLATKAAR(Ala-Pro-Arg-Lys-Gln-Leu-Ala-Thr-Lys-Ala-Ala-Arg) 12 C56 H103 N21 O15 1309 94.82
21 QNIIPASTGAAK(Gln-Asn-Ile-Ile-Pro-Ala-Ser-Thr-Gly-Ala-Ala-Lys) 12 C50 H87 N15 O17 1169 44.40
22 HLQLAIRNDEELNK(His-Leu-Gln-Leu-Ala-Ile-Arg-Asn-Asp-Glu-Glu-Leu-Asn-Lys) 14 C72 H121 N23 O24 1691 83.11
23 VTIAQGGVLPNIQA(Val-Thr-Ile-Ala-Gln-Gly-Gly-Val-Leu-Phe-Asn-Ile-Gln-Ala) 14 C61 H105 N17 O19 1379 74.36
* EIA10, which has the lowest lipid accumulation, is shown in bold in the table.
2.2. Effects of EIA10 on Body Composition in High-Fat Diet (HFD)-Fed Mice
The impact of EIA10 on body weight and fat composition was evaluated in HFD-fed mice. The
experimental design is described in Section 3.8. After five weeks of continuous administration of
positive control (orlistat) or EIA10, the weight of HFD-fed mice treated with orlistat and EIA10
decreased significantly compared to that of HFD-fed mice (Figure 2A). The total energy intake over 10
weeks was 1062.21 kcal for the HFD group, 1026.01 kcal for the HFD+EIA10 group, and 1031.35 kcal for
the HFD+Orlistat group (Table 2). No significant difference was observed in the food intake between
different drug groups, indicating that neither orlistat nor EIA10 had any effect on the appetite of the
HFD-fed mice (Table 2). Dual-energy X-ray absorptiometry (DXA) analysis of body composition, fat
mass, and body weight revealed that fat in the HFD group appeared as increased liver size and higher
amount of white fat tissue (instinctive, subcutaneous, and epididymal) and interscapular darker fat
tissue compared to the fat in the control group (Table 2). Interestingly, EIA10 treatment significantly
reduced white fat tissue weight and the general dispersion of fat (p < 0.05) and completely normalized
brown adipose tissue weight (Table 2).
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(CON) group. ** p < 0.01 vs. HFD group (n = 8 per group). HFD, high-fat diet; Orl, Orlistat. 
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Epididymal adipose tissue 
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Interscapular adipose tissue 
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Liver weight (g) 1.23 ± 0.27 1.72 ± 0.16 ## 1.22 ± 0.25 ** 1.14 ± 0.12 ** 
Figure 2. (A) Body weight and (B) liver histology of HFD group mice.
Glu-Ile-Ala-Gln-Asp-Phe-Lys-Thr-Asp-Leu (EIA10) reduces lipid accumulation in the liver
and adipose tissue. (C) Histological analysis of the liver and epididymal adipose tissue by hematoxylin
and eosin (H&E) staining and Oil Red O staining. Scale bar: 100 um (D) Mean adipocyte area (µm2).
(E) Mean Oil Red O staining in hepatocytes area (µm2). Data are expressed as mean ± standard error of
the mean. ## p < 0.01 vs. control (CON) group. ** p < 0.01 vs. HFD group (n = 8 per group). HFD,
high-fat diet; Orl, Orlistat.
Table 2. Effects on body weight, liver weight, adipose tissue, and biochemical parameters.
CON HFD HFD+EIA10 HFD+Orlistat
Initial body weight (g) 22.61 ± 2.56 22.47 ± 0.36 23.07 ± 0.33 23.55 ± 0.07
Final body weight (g) 28.41 ± 0.15 43.12 ± 0.09 ## 37.38 ± 2.55 ** 36.11 ± 3.92 **
Body weight gain (g) 5.80 ± 0.33 20.65 ± 0.92 ## 12.31 ± 2.54 ** 12.56 ± 0.45 **
Total energy intake (kcal) 935.19 ± 43.12 1062.21 ± 16.19 ## 1026.01 ± 2.60 1031.35 ± 26.32
Epididymal adipose tissue weight (g) 0.67 ± 0.17 2.19 ± 0.28 ## 2.06 ± 0.34 ** 1.90 ± 0.48 **
Subcutaneous adipose tissue weight (g) 0.66 ± 0.31 4.76 ± 0.39 ## 3.36 ± 0.58 ** 3.11 ± 0.53 **
Interscapular adipose tissue weight (g) 0.19 ± 0.05 0.26 ± 0.04 # 0.22 ± 0.06 0.26 0.04 *
Total fat weight (g) 3.99 ± 0.71 18.15 ± 0.33 ## 12.71 ± 0.78 ** 13.71 ± 1.09 **
Liver weight (g) 1.23 ± 0.27 1.72 ± 0.16 ## 1.22 ± 0.25 ** 1.14 ± 0.12 **
TG (mg/dL) 109.44 ± 2.60 248.74 ± 4.62 ## 140.25 ± 5.23 ** 115.52 ± 4.66 **
TC (mg/dL) 95.06 ± 2.69 132.65 ± 4.52 ## 107.46 ± 5.15 ** 113.26 ± 3.40 **
HDL (mg/dL) 75.81 ± 2.64 52.35 ± 3.19 ## 74.49 ± 2.57 ** 72.05 ± 4.38 **
LDL/VLDL (mg/dL) 19.25 ± 3.71 80.30 ± 4.12 ## 32.97 ± 3.42 ** 41.21 ± 2.59 **
Glucose (mg/dL) 121.13 ± 8.41 175 ± 9.75 ## 137 ± 11.47 ** 160.78 ± 13.62 **
ALT (U/L) 45.38 ± 8.10 98.50 ± 13.54 ## 58.75 ± 13.16 ** 44.75 ± 8.38 **
AST (U/L) 110.00 ± 10.90 159.63 ± 9.26 ## 99.20 ± 20.00 ** 113.88 ± 16.17 **
All data represent mean val es± standard error of the mean. Significant differences at # p < 0.05, ## p < 0.05 compared
with the control group. Significant differences at * p < 0.05, ** p < 0.01 compared with the HFD group. TG: triglyceride;
TC: total cholesterol; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; VLDL:
Very low-density lipoprotein cholesterol; ALT: alanine aminotransferase; AST: aspartate aminotransferase.
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2.3. Effects of EIA10 on Lipid Accumulation and Hepatocellular Damage
To confirm the reduction in fat mass after EIA10 treatment, we performed histological analysis of
both liver and epididymal fat tissues. The liver was dark red and smooth in the control group, whereas
the liver in the HFD group was larger, white, smooth, and greasy on the surface, and had convex
edges or medial edges (Figure 2B). The color of the liver in the EIA10 group was healthy. Studies have
shown that although the number of fat cells in the body does not increase in adult mice with increase
in energy accumulation and weight, the size of the fat cells in the body does increase [22]. After H&E
staining, the liver tissue was observed by electron microscopy (Figure 2C) and revealed that control
group hepatocytes were arranged in a reasonably orderly manner, with nuclei in the central part of the
cells, abundant cytoplasm, and clear cell boundaries. However, in the HFD group, liver cells were
loosely arranged, more cells were swollen, and many large fat vacuoles could be seen in the cytoplasm.
The nuclei were located at the edges of the cells, and fat droplets were deposited in the cells, indicating
severe fatty liver degeneration.
Treatment with EIA10 resulted in a more orderly arrangement of the liver cells, reduced the
number of fat vacuoles in the cytoplasm, and altered the shape of the hepatocytes to one similar to that
of the control group. Similarly, the epididymal fat tissues of mice stained with H&E showed that the fat
cells in the control group were uniform in size and compactly arranged, whereas the fat cells in the HFD
group were significantly larger and more disorderly than those in the control group (Figure 2C). The
size of the adipose cells in mice in the EIA10 group was lower than that of the HFD group (Figure 2D),
suggesting that EIA10 has an inhibitory effect on fat accumulation in adipose tissue induced by feeding
with HFD. The results of Oil Red O staining in frozen sections of liver tissue showed that there were
large areas of lipid droplets in the livers of HFD group mice, whereas EIA10-treated livers showed a
significantly reduced number of lipid droplets in the liver (Figure 2C,E). These results showed that
oral administration of EIA10 could effectively reduce the hepatic lipid levels in HFD-fed mice and
showed a protective effect on the liver against HFD-induced steatosis.
2.4. Effects of EIA10 on Blood Biochemical Parameters
Obesity occurs when energy intake is higher than consumption, and the associated imbalance in
lipid synthesis and metabolism of fat results in fatty liver, high blood pressure, diabetes, and other
metabolic syndromes [23]. Obesity, accompanied by lipid metabolism disorder, glucose metabolism
disorder, and abnormal blood glucose levels, has been shown to lead to increased blood TC, TG, and
LDL-C levels [24]. Studies have shown that peptide compounds can potentially improve reverse
cholesterol transport, thereby alleviating dyslipidemia in the HFD mouse model and also benefiting
obese patients [25]. In this study, HFD was successfully used to induce dyslipidemia in mice, including
weight gain, fat accumulation in the liver, and impaired blood glucose tolerance. Compared with
the control group, serum levels of TC, TG, and LDL-C were significantly higher in the HFD group
(Table 2). EIA10 improved dyslipidemia in HFD-fed obese mice and significantly reduced the levels
of TC, TG, and LDL-C in HFD-fed mice (Table 2). Researchers have shown that peptides that can
increase serum HDL-C levels and their ability to carry cholesterol [26] and lower LDL-C and TG
levels in serum can reduce dyslipidemia [27]. In this study, compared with HFD group mice, EIA10
significantly increased serum HDL-C levels and significantly reduced serum LDL-C and TG levels,
thereby inhibiting the accumulation of TG in the liver. Moreover, serum aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) levels that were significantly increased in HFD-fed mice
were significantly reduced by EIA10 (Table 2). These results indicate that EIA10 can effectively balance
lipid levels in HFD mice and alleviate liver injury induced by high-fat diet to some extent.
2.5. Effects of EIA10 against Diet-Induced Impaired Glucose Homeostasis and Insulin Resistance
One of the manifestations of obesity is the excessive deposition of TG and the inhibition of fat
metabolism by insulin [28]. The resulting influx of large amounts of non-esterified fatty acids (NEFAs)
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into the liver may further impair liver metabolism, leading to increased liver glucose production and
TG-rich lipoprotein levels [29].
To compare the differences in glucose metabolism of mice during this experiment, the mice were
fasted for 12 h and orally administered glucose at a dose of 1 g/kg, and blood was collected from the
tail vein (described in Section 3.12.). Blood glucose concentrations were measured after collection at 30
min, 60 min, 90 min, and 120 min, and serum insulin was measured at −30 min and 30 min. The blood
glucose of mice reached a peak 30 min after glucose administration at 250 mg/dL and then declined
until it returned to the original level at 120 min (Figure 3A). The oral glucose tolerance test (OGTT)
results revealed that, compared with the control group, although the blood glucose level of the HFD
group mice still returned to the control group level, the highest value of blood glucose in the HFD
group was significantly higher than that of the control group (Figure 3A).
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Mice can be considered diabetic when their fasting blood glucose concentration is >300 mg/dL.
In this experiment, none of the mice became diabetic, and their regulation of glucose metabolism
remained within normal limits. To further explore the changes in blood glucose concentrations in each
group, the area under the OGTT curve (AUC) was calculated (Figure 3B). AUC is derived from the
time–glucose concentration curve, which reflects the geometric mean of the five-point blood glucose
levels in the OGTT. Compared with the blood glucose at single points, the AUC is a better indicator
of the changing trend in blood glucose levels over time. The area under the curve (AUC) in mice
showed that the AUC values of the EIA10 and orlistat groups were significantly lower than those of the
HFD group (p < 0.05, Figure 3B). Insulin resistance (IR) is the central link and pathogenesis of various
metabolic abnormalities [30]. IR also increases the content of FFAs and TGs, reduces the inhibitory
effect of insulin on gluconeogenesis and glucose release, and leads to the increase of blood glucose [31].
In this study, to further investigate the impact of EIA10 on glucose and lipid metabolism, an insulin
resistance experiment was conducted. The results showed that, compared with the CON group, the
insulin secretion level of HFD mice was significantly increased after oral glucose. Compared with
HFD, the insulin secretion level of the EIA10 group decreased after oral glucose, and the difference
was significant (p < 0.05, Figure 3C,D).
In this study, the mice in the HFD group showed increased TC, TG, LDL, hepatic insulin resistance
index (IRI), and HDL levels (Table 2, Figure 3E,F), which was consistent with the impairment of glucose
and lipid metabolism at the onset of obesity. The mice in the HFD group showed liver steatosis,
which is closely related to obesity. Five weeks of oral EIA10 intervention improved glucose and lipid
metabolism and alleviated IR in the obese mice to some extent.
Orlistat is currently the only non-prescription drug available for weight loss and was used as a
positive control in this study. Compared with orlistat, EIA10 has all natural, non-toxic benefits. The
results of this experiment showed that both orlistat and EIA10 could inhibit lipid accumulation and
significantly reduce TC and TG levels in serum in terms of reducing body fat content, and there was
no significant difference between them. There are many intolerable side effects of orlistat including
diarrhea, flatulence, and fecal incontinence. However, EIA10 is assumed to have a benign regulatory
effect on the development of obesity and lipid metabolism as an all-natural agent. Therefore, it is in
need of further investigation as to whether EIA10 causes side effects such as fecal incontinence and
diarrhea, and which organs are targeted by EIA10 in a clinical study.
2.6. Effects of EIA10 on Lipogenic Molecule Signaling Pathway
Adiponectin activates AMPK in adipose tissue and inhibits sterol regulatory element-binding
transcription factor 1 (SREBP-1c) precursor cleavage and nuclear translocation, resulting in the
inhibition of SREBP-1c-mediated adipogenesis [32]. In this study, we measured the protein levels of
adiponectin in mouse epididymal adipose tissue and observed that EIA10 improved the adiponectin.
Therefore, EIA10 could inhibit fat accumulation in mice by improving the adiponectin and reducing the
plasma leptin concentration, thereby reducing fat synthesis (Figure 4A,B). SREBPs are closely related
to a series of metabolic diseases including dyslipidemia, insulin resistance, diabetes, and nonalcoholic
fatty liver disease. Lipid-lowering effects caused by several other peptide compounds have also
been attributed to the decrease in SREBP-1c [33]. In this experiment, mRNA and protein levels of
SREBP-1c were lower in the adipose tissue of HFD-fed mice treated with EIA10 than in the HFD group
(Figure 4C,D), suggesting that EIA10 regulates fatty acid synthesis by regulating the expression of
SREBP-1c to lower lipid levels.
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by real-time PCR. (D) Western blotting. “+” and “–” meaning with or without HFD treatment. Data
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HFD group (n = 8 per group). HFD, high-fat diet; Orl, Orlistat.
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To further clarify the lipid-lowering mechanism of EIA10, we investigated the inhibitory effects of
EIA10 on fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) gene expression level. FAS is a
polypeptide chain with distinct enzyme activity necessary for fatty acid biosynthesis. In the cytoplasm,
acetyl-CoA is carboxylated by acetyl-CoA carboxylase (ACC) to form malonyl-CoA. Malonyl-CoA
and nicotinamide adenine dinucleotide phosphate (NADPH) are used by FAS to produce palmitic
acid, which is the most common saturated fat in plants and animals [34,35]. Therefore, FAS inhibition
becomes an essential goal for weight prevention and lipid modulation. The results of this experiment
showed that EIA10 had an inhibitory effect on both FAS and ACC gene expression (Figure 5A,B),
indicating that EIA10 could effectively inhibit the synthesis and accumulation of fat in vivo, which may
be one of the mechanisms of EIA10 to improve obesity and lipid metabolism in mice. We observed the
effect of EIA10 on FAS activity in liver tissues by immunohistochemistry (IHC). The results showed
that EIA10 also inhibited FAS in liver tissue (Figure 5C).
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Figure 5. Effect of EIA10 on (A,B) protein of lipogenic enzyme in epididymal adipose tissue of animals
treated with different groups as quantified by Western blot. (“+” and “–” meaning with or without
HFD treatment). (C) IHC-stained FAS is shown in mouse liver tissues (left and right images in C, right
images in C represent areas in the black rectangles). Scale bar: 50um Data are expressed as mean ±
standard error of the mean. # p < .01 vs. control (CON) group. ** p < .01 vs. HFD group (n = 8 per
group). HFD, high-fat diet; Orl, Orlistat.
FAS is regulated by peroxisomal proliferator-activated receptor γ (PPARγ), and its upregulation
increases the amount of lipid synthesized from acetyl-CoA, causing the accumulation of TGs in liver
tissues. In this study, we found that EIA10 reduced HFD-induced fat synthesis and accumulation
through SREBP-1c regulation, leading to lipid reduction. Most of the genes involved in adipogenesis
are induced and regulated by PPARγ and C/EBP-α [36]. As shown in Figure 4C,D, EIA10 decreased the
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mRNA and protein levels of PPARγ in the HFD group mice. FABP4 is a target gene of PPARγ and
is involved in adipocyte differentiation [37]. In this study, we found that EIA10 downregulated the
expression of PPARγ, C/EBP-α, FAS, and SREBP-1c, and also significantly decreased the protein levels
of PPARγ, C/EBP-α, SREBP-1c, and FABP4 (Figure 4C,D).
3. Materials and Methods
3.1. Biological Materials
The third instar A. dichotoma larvae used in the experiment were purchased from Geoje Insect
Farm (Gyeongnam-si, Gyeongsangbuk-do, Korea) in 2019. The larvae were maintained on a diet of
fermented sawdust, and third instar larvae were collected based on the size of their head capsules.
We used third instar larvae for this study because they have a longer larvae period and eat a large
amount of feed compared to first or second instar larvae. The insects were purchased and used after
washing and freezing. Pepsin and trypsin were obtained from Sigma-Aldrich (St Louis, MO, USA);
Protease NP (PNP), Pancreatin (p), Alphalase NP (AP), Food Pro Alkaline protease (AK), Promod
278P (PM) Vision Biochem, Alcalase (AC), Neutrase (NT), and Protamex (PMX) were purchased from
Daejong Corporation.
3.2. Enzymatic Hydrolysis
A. dichotoma larvae were lyophilized (Lyoph-Pride 100, Ilshinbiobae, Dongducheon-si, Korea),
pulverized into a powder using a grinder (VMO159A, Vitamix, Cleveland, OH, USA), and hydrolyzed
with enzymes according to the method described by Park et al. [38]. Table 3 summarizes the optimal pH,
temperature, and characterization of different enzymes. Briefly, 100 mL of distilled water were added
to 10 mg of the freeze-dried A. dichotoma larvae powder followed by 0.1 µL (or mg) of an enzyme. The
enzymatic hydrolysis was performed for 6 h to achieve an optimal hydrolytic level and was followed
by direct heating at 100 ◦C for 10 min to inactivate the enzymes. After the enzyme-inactivated mixture
was centrifuged at 2000 rpm (Optima XE100 ultracentrifuge, Beckman Coulter, Miami, FL, USA), the
supernatant was vacuum-filtered and subjected to ultrafiltration (UF, Ultracel PL-10, Millipore, Billerica,
MA, USA) with Amicon® Stirred Cells (Millipore, Billerica, MA, USA) membranes (membrane cut-off:
100 kDa, 10 kDa, 5 kDa, 1 kDa) in a nitrogen atmosphere at a pressure of 5 bar. The proteins were
fractionated from 100 kDa or higher to 10 kDa, 10 kDa to 5 kDa, 5 kDa to 1 kDa, or 1 kDa or lower
molecular weight, filtered, and lyophilized to obtain the hydrolysate, which was stored at −20 ◦C until
further use.
Table 3. Reaction conditions of different enzymes.
Abbreviation Temperature (◦C) pH Addition (%) Inactivation
Pancreatin P 50 7 1 80 ◦C, 10 min
Food Pro Alkaline protease AK 50 7 1 80 ◦C, 10 min
Alphalase NP AP 50 7 1 80 ◦C, 10 min
Promod 278P PM 50 7 1 80 ◦C, 10 min
Alcalase AC 50 7 1 80 ◦C, 10 min
Neutrase NT 50 7 1 80 ◦C, 10 min
Protamex PMX 50 7 1 80 ◦C, 10 min
Protease NP PNP 50 7 1 80 ◦C, 10 min
Trypsin TS 38 7 1 80 ◦C, 10 min
Pepsin PS 38 2 (HCl 35%) 1 pH 7.5 (NaOH 5N)
Control - 50 7 - 80 ◦C, 10 min
3.3. Cell Culture, Differentiation, and Treatments
The 3T3-L1 cells were obtained from the Korean Cell Line Bank (Seoul, Korea). They were cultured
and maintained in Dulbecco’s modified Eagle medium (DMEM) at 37 ◦C in a humidified atmosphere
of 5% CO2. Additionally, 2-day post-confluent preadipocytes (designated day 0) were cultured in
a 2-day differentiation medium composed of DMEM, 0.5 mM IBMX, 1 µM dexamethasone, and 5
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µg/mL insulin to induce differentiation. The cells were then cultured in a DMEM containing 5 µg/mL
insulin for another 2 days. The medium was replaced every 2 days until the cells had accumulated
intracellular lipid droplets [39].
3.4. Determination of the Deposition of Lipids by Oil Red O Staining
Cells were seeded in 6-well plates, and adipocyte differentiation was induced for 8 days. On day
8, the cells were fixed with 10% buffered formalin and stained with Oil Red O solution for 60 min at
room temperature. Images of lipid droplets in the 3T3-L1 adipocytes were captured using a Leica
DMi1 microscope (Leica, Germany).
3.5. Fast Protein liquid Chromatography (FPLC)
To separate and purify the fraction possessing anti-obesity efficacy obtained by UF into a
single-peptide fragment, the ultrafiltrate was separated and purified step by step using three FPLC
columns (Akta Avant 25, GE Healthcare, Uppsala, Sweden). Ion-exchange chromatography (IEC) was
performed using Mono-Q 5/50 GL (5*50 mm, 10 µm), using binding buffer (50 mM phosphate buffer
(pH 7)) and elution buffer (1 M NaCl-phosphate buffer, pH 7). The elution buffer concentration was
increased from 0% to 100%, the column volume value was 20, flow rate 2 mL/min, and absorbance 280
nm. After IEC, HiPrep 26/10 desalting column binding buffer (50 mM phosphate buffer (pH 7)) was
used at a flow rate of 10 mL/min to remove the salt in the sample. Next, reversed-phase, preparative
fractionation was used to separate and purify the fractions with anti-obesity efficacy from the IEC
eluate. Separation and purification were performed using an Agilent Zorbax 300SB-C18 PrepHT
(7 µm, 21.2 × 250 mm) column with acetonitrile (ACN) (gradient from 100% to 0%) and water as the
mobile phase at a flow rate of 3 mL/min and absorbance of 280 nm. The active phase fraction from the
reversed-phase preparative analysis was analyzed at 280 nm at a flow rate of 0.5 mL/min at 45% ACN
with an Agilent Zorbax 300SB-C18 (5 µm, 4.6 × 250 mm) reversed-phase column.
3.6. Analysis of Target Peptides
For nanoUPLC Orbitrap Fusion Lumos MS (Thermo ScientificTM, Waltham, MA, USA), peptide
digests were done using online reversed-phase chromatography. Peptides above the threshold of 5e3
were selected for fragmentation with dynamic exclusion after a 15-s scan at 10 ppm tolerance. Spectra
were searched against the UniProt-A. dichotoma database using Proteome Discoverer Sorcerer 2.2.2
with an SEquest-based search algorithm. Comparative analysis of proteins identified in this study
was performed using Scaffold 4 Q+S. Protein probabilities were assigned by the Peptide Prophet
algorithm [40] with Scaffolds delta-mass correction. Protein identifications were accepted if they could
be established at > 99.0% probability to achieve an FDR < 0.1%. Protein probabilities were assigned by
the Protein Prophet algorithm [41]. Peptide identifications and protein probabilities were accepted
at > 11.0%, and at least 2 identified peptides were grouped based on similar peptides that could not
be differentiated based on parsimony/parsimony principles. For peptide and protein comparative
analysis, MS/MS analysis alone was used to verify the peptide identifications. For protein analysis,
comparative analysis of the peptides and proteins was done using MS/MS analysis alone using MSMS
and MSMS analysis with a scaffolding algorithm, and the protein probability was assigned to tandem
(sample Mudpit_A4_2: A4_1). The data were deposited into the ProteomeXchange Consortium via the
PRIDE [42] partner repository with the dataset identifier PXD019661 and 10.6019/PXD019661.
3.7. Peptide Synthesis
The peptides listed in Table 1 were provided by Sewon Biotech (Seoul, Korea), and the method
for preparing the peptides is briefly described below. Peptides were synthesized by solid-phase
peptide synthesis using fluorenylmethylocycarbonyl-(Fmoc)/tertiary-butyl-(tBu) protocols, and the
assembly of amino acid residues was performed in the Syro-I automatic peptide synthesizer (Biotage,
Sweden). 2-Chlorotrityl resin (Beadtech, Korea) was used during synthesis and for all first-amino acid
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attachments. Introduction of Fmoc-amino acids was carried out with a mixture of hexafluorophosphate
benzotriazole tetramethyl uronium/1-hydroxybenzotriazole/diisopropylethylamine (1:1:2), and Fmoc
groups were removed by treating the resin with 20% piperidine in dimethylformamide.
After assembling all amino acid residues, the crude peptides were cleaved from the peptide resin
with a mixture of trifluoroacetic acid/triisopropylsilane/water (95:2.5:2.5) for 2 h at room temperature.
Peptide precipitations were then isolated from the cleavage solution with cold diethyl ether and washed
four times with cold ether. The purity and the identity of peptides were confirmed by analytical
high-performance liquid chromatography (HPLC) (Agilent 1100, Agilent Technologies, Santa Clara,
CA, USA) and by liquid chromatography–mass spectrometry (LC/MS) (Thermo Scientific™ LTQ XLTM
IonTrap mass spectrometer, San Jose, CA, USA). Following the characterization of the products, the
peptides were purified by preparative HPLC (Waters 2998, Milford, MA, USA). The purified peptides
were lyophilized, and homogeneity (≥95%) of the compound was confirmed by analytical HPLC and
by LC/MS. Finally, each peptide was sequenced using de novo sequencing with the Xcalibar Qual
Browser program (ver. 4.2.47, Thermo Fisher Scientific, Bremen, Germany).
3.8. Experimental Animals, Diet, and Treatments
Four-week-old male C57BL/6 mice were purchased from the Nara Bio Animal Center (NARA
Biotech, Seoul, Korea) All experiments were approved by the Institutional Animal Care and Use
Committee of Konkuk University (14 July 2019). All possible efforts were made to minimize the
suffering and the animal count utilized in this study (KU19102). The mice were randomly divided
into the following two groups after 1 week of acclimatization: n = 8 in the control group, fed a normal
diet (Control, fat content of 10% kcal), and n = 30, fed a high-fat diet (HFD, fat content of 60% kcal).
Mice were registered daily for food intake, and their body weights were assessed twice a week. After
5 weeks, mice with a body weight 20% higher than that of the control group were picked and divided
randomly into three groups (n = 8/group): HFD + EIA10, 100 mg/kg/d; and HFD + orlistat, 60 mg/kg /d
for 5 weeks. As a positive control, Orlistat was used. After 12 weeks, the mice were subjected to fasting
overnight and sacrificed (Figure 2A). Blood samples were harvested for further analysis. Sections of
epididymal adipose and liver tissues were fixed in 10% formaldehyde for histological analyses and
frozen in liquid nitrogen.
3.9. Body Fat Composition Analysis
Dual-energy X-ray absorptiometry (DXA) measurements were used to compare the body fat. DXA
measurements were performed after 4 weeks of administration using a total-body scanner (InAlyzer
dual X-ray absorptiometry, Medikors, Gyeonggi, Korea). Data were obtained once with low energy
and once with high energy.
3.10. Histological Analysis
Liver and epididymal adipose tissues were dissected and embedded in paraffin for histological
examination. Tissue blocks were cut into 4-µm thick sections that were stained with hematoxylin
and eosin. Frozen liver sections were cut into 8-µm thick sections that were stained with Oil Red O.
Adipocyte sizes were assessed using a microscope under 200×magnification to measure tissue size.
3.11. Biochemical Analysis
Through heart puncture, blood samples were collected and serum was isolated through
centrifugation (3000 rpm for 20 min) and processed before further study at −80 ◦C. An automated
analyzer (Abaxis VETSVAN VS2 Chemistry Analyzer, Union City, CA, USA) assessed serum levels of
blood urea nitrogen, alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase
(AST), total protein, serum albumin, and electrolytes. Using a fast blood lipid analyzer (OSANG
Healthcare Lipid Pro, Anyang, Korea), total cholesterol (TC), low-density lipoprotein cholesterol
(LDL), high-density lipoprotein cholesterol (HDL), and TG were calculated. Adiponectin was analyzed
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by Western blotting, and leptin was quantified using a leptin enzyme-linked immunosorbent assay
(ELISA) kit (MERCK, DHB, Germany).
3.12. Oral Glucose Tolerance Test (OGTT) and Insulin Levels
An oral glucose tolerance test (OGTT) to determine the clearance of a standardized glucose
load was performed after 5 weeks of oral administration. Plasma glucose was determined under
postabsorptive conditions with blood collected at time -30 and 0 and then after oral administration of 1
g/kg of glucose at 30, 60, 90, and 120 min. Using a Blood Glucose Testing System (891 Hogye-Dong
Dongan-gu, Anyang, Gyeonggi-do, Korea), blood samples were measured from the tail veins. A mouse
ultrasensitive insulin ELISA package (ALPCO, Salem, NH, USA) was quantified for serum insulin.
3.13. Estimation of Insulin Resistance Indices
The hepatic insulin resistance index (hepatic IRI) was estimated by using the validated method of
Matsuda and DeFronzo [43]. Insulin resistance was assessed using the homeostasis model assessment
of insulin resistance (HOMA-IR). HOMA is a mathematically derived model of glucose–insulin
feedback [44].
3.14. mRNA Analysis
Total cellular RNA was isolated from the epididymal adipose tissue of each group of mice using
TRIzol. The first strand of complementary DNA (cDNA) was synthesized using Superscript II reverse
transcriptase (Invitrogen). The conditions for RT-PCR were similar to those previously described [45].
Quantitative real-time PCR was carried out using a Thermal Cycler Dice TP850 (Takarabio Inc., Shiga,
Japan) according to the manufacturer’s protocol. The primers used for gene expression analysis are
presented in Table 4.
Table 4. Primers used in reverse transcriptase–polymerase chain-reaction analysis.
Gene Name Sequence
C/EBP-α Forward 5-CGT CTA AGA TGA GGG AGT C-3Reverse 5-GGC ACA AGG TTA CTT CCT-3
PPAR-γ Forward 5-GAA AGA CAA CGG ACA AAT CAC-3
Reverse 5-GAA ACT GGC ACC CTT GAA-3
FAS
Forward 5-CTT GGG TGC TGA CTA CAA CC-3
Reverse 5-GCC CTC CCG TAC ACT CAC TC-3
SREBP-1c
Forward 5-CTT CTG GAG ACA TCG CAA AC-3
Reverse 5-GGT AGA CAA CAG CCG CAT C-3
GAPDH
Forward 5-GCA CAG TCA AGG CCG AGA AT-3
Reverse 5-GCC TTC TCC ATG GTG GTG AA-3
C/EBP-α: CCAAT/enhancer-binding protein-α; PPAR-γ: peroxisome proliferator-activated receptor-γ;
FAS: fatty acid synthase; SREBP-1c: Sterol regulatory element-binding protein 1; GAPDH:
glyceraldehyde-3-phosphate dehydrogenase.
3.15. Protein Quantification
Frozen epididymal adipose tissues from mice were homogenized in liquid nitrogen. Tissue lyses
were lysed in a radioimmunoprecipitation lysis buffer containing 1% protein inhibitor cocktail [46].
They were transferred to a nitrocellulose blotting membrane and blocked with 5% skim milk, incubated
overnight with primary antibodies purchased from Cell Signaling Technology, and then incubated
with secondary antibodies for 2 h. Equal protein loading was ascertained using Ponceau S staining
of the blotted membranes. With the help of an improved chemiluminescence detection reagent, the
antibody-specific proteins were visualized and quantified using ImageJ tools.
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3.16. Statistical Analysis
The results shown in this study are from at least three experiments. The data are expressed as the
mean ± standard error of the mean. The data were analyzed using SPSS version 11.5 for Windows
(SPSS Inc., Chicago, IL, USA). The one-way variance analysis (ANOVA) research of post-hoc analyses
by the Student–Newman–Keuls test carried out multi-group analyses of the means. To equate the
means of two or more sets of variables that were not usually distributed, Dunnett’s multiple range test
was used. Statistically significant was set at p < 0.05 and p < 0.01.
4. Conclusions
This study describes the regulation of lipid metabolism by novel peptide EIA10 from A. dichotoma
larvae, which helps to extend the nutritive and medicinal value of A. dichotoma larvae. A. dichotoma
larvae were enzymatically hydrolyzed and further purified using tangential flow filtration and different
chromatographic methods to obtain Gln-Ile-Ala-Gln-Asp-Phe-Lys-Thr-Asp-Leu (EIA10) as the peptide
with the highest anti-adipogenic effect among all of the larvae peptides. EIA10 showed the lowest
lipid accumulation of 3T3-L1 adipocyte lipid droplets in vitro.
EIA10 effectively alleviated the symptoms of fatty liver, reduced lipid accumulation, catalyzed
the decomposition of TG and TC, and reduced blood lipid levels and body weight of HFD-fed mice.
Lipid synthesis can be prevented by inhibiting the expression of related genes. EIA10 inhibited PPARγ
signaling as well as the development and progression of obesity. It can be seen that clinical treatment
using EIA10 for lipid regulation and weight loss has a good development prospect.
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